SD Cancer Research Results

SD, Stable Disease: Click to Expand ⟱
Source:
Type:
Stable Disease
Scientific Papers found: Click to Expand⟱
7986- itraC,    Open-label, exploratory phase II trial of oral itraconazole for the treatment of basal cell carcinoma
- Trial, BCC, NA
Dose↝, TumCP↓, HH↓, TumVol↓, SD↑,
8127- LF,    Phase I trial of oral talactoferrin alfa in refractory solid tumors
- Trial, Var, NA
Imm↑, NK cell↑, Dose↝, toxicity↓, IL18↑, SD↑, TumCG↓, OS↑,
2038- PB,    A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies
- Trial, Var, NA
Dose∅, *toxicity↝, BioAv↑, SD↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Transcription & Epigenetics(tgid=7) ⓘ

SD↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

HH↓, 1,   TumCG↓, 1,  

Migration(tgid=13) ⓘ

TumCP↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL18↑, 1,   Imm↑, 1,   NK cell↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Dose↝, 2,   Dose∅, 1,  

Functional Outcomes(tgid=23) ⓘ

OS↑, 1,   toxicity↓, 1,   TumVol↓, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Functional Outcomes(tgid=23) ⓘ

toxicity↝, 1,  
Total Targets: 1

Scientific Paper Hit Count for: SD, Stable Disease
1 itraconazole
1 Lactoferrin/Talactoferrin
1 Phenylbutyrate
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:1  prod#:%  Target#:1236  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page